Literature DB >> 8760087

Expression of AT1A and AT1B angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats.

O Jöhren1, J M Saavedra.   

Abstract

The gene expression of angiotensin II receptor subtypes AT1A and AT1B was localized in the forebrain of 2-wk-old rats by in situ hybridization histochemistry and compared with [125I]Sar1-angiotensin II binding patterns. AT1A receptor mRNA was expressed in circumventricular organs, in hypothalamic nuclei like the paraventricular nucleus, in the lateral olfactory tract, in the basolateral amygdaloid and anterior olfactory nuclei, and in the piriform cortex. No AT1B receptor mRNA was detected in these areas. AT1A and AT1B receptor mRNA was detected in the hippocampus, cingulate cortex, and choroid plexus. No forebrain area studied expressed AT1B receptor mRNA exclusively. Most often, a good match for receptor mRNA and binding was found. In some areas, apparent mismatches suggested receptor formation elsewhere (median eminence) or receptor presence in local neuronal circuits (hippocampus, cingulate, and piriform cortex). Our results support the hypothesis that AT1A receptors are involved in the classical central functions of angiotensin II. Both AT1A and AT1B receptors may play roles in cortical and limbic system function, particularly early in development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760087     DOI: 10.1152/ajpendo.1996.271.1.E104

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  19 in total

Review 1.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.

Authors:  Helge Müller-Fielitz; Margot Lau; Cathleen Geißler; Lars Werner; Martina Winkler; Walter Raasch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 4.  The intricacies of the renin-angiotensin-system in metabolic regulation.

Authors:  Erin B Bruce; Annette D de Kloet
Journal:  Physiol Behav       Date:  2016-11-22

5.  AGTR1 gene variation: association with depression and frontotemporal morphology.

Authors:  Warren D Taylor; Sophiya Benjamin; Douglas R McQuoid; Martha E Payne; Ranga R Krishnan; James R MacFall; Allison Ashley-Koch
Journal:  Psychiatry Res       Date:  2012-06-15       Impact factor: 3.222

6.  Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.

Authors:  Sonia Villapol; Alexandra K Yaszemski; Trevor T Logan; Enrique Sánchez-Lemus; Juan M Saavedra; Aviva J Symes
Journal:  Neuropsychopharmacology       Date:  2012-08-15       Impact factor: 7.853

Review 7.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 8.  Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

9.  Six commercially available angiotensin II AT1 receptor antibodies are non-specific.

Authors:  Julius Benicky; Roman Hafko; Enrique Sanchez-Lemus; Greti Aguilera; Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2012-07-28       Impact factor: 5.046

Review 10.  Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.